TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more
TME PHARM.CONF.IPO EO 1- (0N6A) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, TME PHARM.CONF.IPO EO 1- (0N6A) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
TME PHARM.CONF.IPO EO 1- - Net Assets Trend (None–None)
This chart illustrates how TME PHARM.CONF.IPO EO 1-'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TME PHARM.CONF.IPO EO 1- (None–None)
The table below shows the annual net assets of TME PHARM.CONF.IPO EO 1- from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to TME PHARM.CONF.IPO EO 1-'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
TME PHARM.CONF.IPO EO 1- Competitors by Market Cap
The table below lists competitors of TME PHARM.CONF.IPO EO 1- ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SIG Group AG
STU:1YQA
|
$123.28K |
|
Gudme Raaschou Europæiske Ejendomsaktier
CO:GRIEJD
|
$123.29K |
|
First Trust High Yield Opportunities 2027 Term Fund
NYSE:FTHY
|
$123.30K |
|
QUANEX BLDG PRDS
BE:4Q2
|
$123.33K |
|
Teems Inc.
KQ:134790
|
$123.21K |
|
Angel Oak Financial Strategies Income Term Trust
NYSE:FINS
|
$123.20K |
|
Western Asset Diversified Income Fund
NYSE:WDI
|
$123.17K |
|
ORIOR N (9OI.SG)
STU:9OI
|
$123.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TME PHARM.CONF.IPO EO 1-'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares TME PHARM.CONF.IPO EO 1-'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently TME PHARM.CONF.IPO EO 1- utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares TME PHARM.CONF.IPO EO 1-'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TME PHARM.CONF.IPO EO 1- (0N6A) | €- | N/A | N/A | $123.22K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |